PHYSIOLOGICAL INHIBITORS OF COAGULATION IN FULMINANT HEPATIC-FAILURE

被引:13
|
作者
LANGLEY, PG
WILLIAMS, R
机构
[1] UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,DENMARK HILL,LONDON SE5 9RS,ENGLAND
[2] KINGS COLL,SCH MED & DENT,LONDON SE5 9RS,ENGLAND
关键词
PROTEIN-S; PROTEIN-C; ANTITHROMBIN-III; HEPARIN COFACTOR-II; FULMINANT HEPATIC FAILURE;
D O I
10.1097/00001721-199206000-00002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To study the effect of the severe loss of hepatic synthetic function on the inhibitors of coagulation we have measured protein S (total and free), protein C, heparin cofactor II and antithrombin III in 30 patients with fulminant hepatic failure. The results showed severe reduction in all inhibitor levels with mean (+/- SE) values of: protein S, 0.26 +/- 0.03 U/ml; protein C, 0.26 +/- 0.03 U/ml; heparin cofactor II, 0.12 +/- 0.02 U/ml and antithrombin III, 0.21 +/- 0.02 U/ml. Heparin cofactor II was significantly lower than the other inhibitors (P < 0.01). Although the reduction in free protein S was significant in fulminant hepatic failure as compared to normal subjects (0.40 +/- 0.05 U/ml compared to 1.02 +/- 0.08 U/ml, P < 0.001), the ratio of free to total protein S was significantly increased (0.67 +/- 0.02 compared to 0.40 +/- 0.04, P < 0.01). Prothrombin time (INR) was significantly inversely correlated with total protein S (r = -0.56, P < 0.001) and free protein S (r = -0.48, P < 0.01), but not with the ratio of free to total protein S. No significant correlation between the different coagulation inhibitors and other measures of hepatic function could be detected. Although the loss of hepatic synthetic function appears to be the major cause of the loss of coagulation inhibitors, other effects such as increased consumption and rate of clearance may play a role. The balance of these will be reflected in the circulating levels of the coagulation inhibitors.
引用
收藏
页码:243 / 247
页数:5
相关论文
共 50 条
  • [1] PHYSIOLOGICAL TREATMENT OF FULMINANT HEPATIC-FAILURE
    ANTIA, FP
    DESAI, HG
    KALRO, RH
    GANDHI, MK
    [J]. GASTROENTEROLOGY, 1980, 79 (05) : 1098 - 1098
  • [2] INHIBITORS OF HEPATIC DNA-SYNTHESIS IN FULMINANT HEPATIC-FAILURE
    HUGHES, RD
    YAMADA, H
    GOVE, CD
    WILLIAMS, R
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1991, 36 (06) : 816 - 819
  • [3] FULMINANT HEPATIC-FAILURE
    TYGSTRUP, N
    RANEK, L
    [J]. CLINICS IN GASTROENTEROLOGY, 1981, 10 (01): : 191 - 208
  • [4] FULMINANT HEPATIC-FAILURE
    LIDOFSKY, SD
    [J]. CRITICAL CARE CLINICS, 1995, 11 (02) : 415 - 430
  • [5] FULMINANT HEPATIC-FAILURE
    KATELARIS, PH
    JONES, DB
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 1989, 73 (04) : 955 - 970
  • [6] FULMINANT HEPATIC-FAILURE
    MARTIN, P
    PAPPAS, SC
    [J]. DIGESTIVE DISEASES, 1990, 8 (03) : 138 - 151
  • [7] FULMINANT HEPATIC-FAILURE
    FINGEROTE, RJ
    BAIN, VG
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1993, 88 (07): : 1000 - 1010
  • [8] FULMINANT HEPATIC-FAILURE
    RIEGLER, JL
    LAKE, JR
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 1993, 77 (05) : 1057 - 1083
  • [9] FULMINANT HEPATIC-FAILURE
    HETZEL, DJ
    [J]. ANAESTHESIA AND INTENSIVE CARE, 1985, 13 (03) : 272 - 282
  • [10] FULMINANT HEPATIC-FAILURE
    RUSSELL, GJ
    FITZGERALD, JF
    CLARK, JH
    [J]. JOURNAL OF PEDIATRICS, 1987, 111 (03): : 313 - 319